(Fort Worth, TX, USA) —HEALTHPOINT, Ltd., a market leader in pharmaceutical products for skin and soft tissues, has announced the availability of the OASIS^® Burn Matrix, a product that provides a supportive environment to allow healing of second degree and superficial burns.

        An initial launch took place during HEALTHPOINT’S National Sales Meeting in Dallas in March, with nationwide launch this week.

        The OASIS Burn Matrix complements the OASIS Wound Matrix line of products marketed and distributed exclusively by HEALTHPOINT and manufactured by Cook Biotech.

        The OASIS Burn Matrix was designed with several features specifically for burn patients, including increased thickness of the OASIS Burn Matrix that may allow application for an extended time. As frequency of application decreases, less pain may result since repeated dressing changes are often increasingly painful for burn patients

        “OASIS Burn Matrix sets a new standard for the management of donor sites as well as for second degree and superficial burns,” said Dwayne Dixon, Tissue Management Marketing Director. “This provides a new option for patients suffering the effects of serious burns.”

        OASIS Burn Matrix is based on SIS^® Technology, a naturally derived, extracellular matrix created from the submucosal layer of porcine small intestine. The submucosa (found between the mucosal and muscular layers) provides strength to the intestine through a complex organization of structural and functional proteins and other molecules that form a three-dimensional matrix. The submucosa is extracted in a manner that removes all cells but leaves the complex matrix intact. This natural matrix supports the body’s healing process by providing an acellular scaffold that accommodates remodeling of host tissue. This biomaterial combines remarkable strength, flexible handling, and a complex composition.

        In addition to the OASIS Burn Matrix specifically developed for burns, other OASIS products are used in the management of partial and full-thickness skin loss injuries from surgical and trauma wounds; autograft donor sites; pressure, venous, and chronic vascular ulcers; diabetic ulcers; and abrasions, according to HEALTHPOINT.

        Since its inception in 1992, HEALTHPOINT has established a national presence in the research, development, and marketing of branded pharmaceuticals, over the counter drugs, and medical devices for the tissue management, dermatology, and surgical divisions. An aggressive research and development effort has brought HEALTHPOINT’s unique technologies to the market, setting the pace for its highly trained national field sales organization of direct sales representatives. HEALTHPOINT, with over 250 employees, is a DFB Pharmaceuticals, Inc. affiliate company. Based in Fort Worth, Texas, DFB provides technology-driven products, outsourcing services and licensing opportunities to the healthcare industry worldwide through its affiliate companies, contract partners, and branded marketing organizations.

        HEALTHPOINT has an additional office in Canada. Visit HEALTHPOINT’s web site at www.healthpoint.com.

###